Browse ELF3

Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Localizes to the cytoplasm where it has been shown to transform MCF-12A mammary epithelial cells via a novel cytoplasmic mechanism. Also transiently expressed and localized to the nucleus where it induces apoptosis in non-transformed breast epithelial cells MCF-10A and MCF-12A via a transcription-dependent mechanism.
Domain PF00178 Ets-domain
PF02198 Sterile alpha motif (SAM)/Pointed domain
Function

Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. May be a critical downstream effector of the ERBB2 signaling pathway. May be associated with mammary gland development and involution. Plays an important role in the regulation of transcription with TATA-less promoters in preimplantation embryos, which is essential in preimplantation development (By similarity).

> Gene Ontology
 
Biological Process GO:0001701 in utero embryonic development
GO:0001824 blastocyst development
GO:0008544 epidermis development
GO:0022612 gland morphogenesis
GO:0030198 extracellular matrix organization
GO:0030879 mammary gland development
GO:0043062 extracellular structure organization
GO:0048732 gland development
GO:0048771 tissue remodeling
GO:0060056 mammary gland involution
GO:0060443 mammary gland morphogenesis
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003713 transcription coactivator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ELF3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ELF3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ELF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4180.443
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7950.363
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.3130.079
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.3080.0638
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0520.71
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.6320.648
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3440.73
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0250.488
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.9790.192
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.7830.7
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.3750.641
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2770.167
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ELF3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91644.4044.40.00996
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47750750.0242
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ELF3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ELF3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ELF3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ELF3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ELF3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ELF3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolELF3
NameE74-like factor 3 (ets domain transcription factor, epithelial-specific )
Aliases ESE-1; ERT; ESX; E74-like factor 3 (ETS domain transcription factor, serine box, epithelial-specific); E74-l ......
Chromosomal Location1q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ELF3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.